Search Results - "DiMichele, Donna"

The principal results of the International Immune Tolerance Study: a randomized dose comparison by Hay, Charles R.M., DiMichele, Donna M.

“…The International Immune Tolerance Study was a multicenter, prospective, randomized comparison of high-dose (HD; 200 IU/kg/d) and low-dose (LD; 50 IU/kg 3…”
Get full text

Immune tolerance in haemophilia: the long journey to the fork in the road by DiMichele, Donna M.

“…Summary Antibody eradication is the ultimate goal of inhibitor management. The only clinically proven strategy for achieving antigen‐specific tolerance to…”
Get full text

Hemophilia Therapy — Navigating Speed Bumps on the Innovation Highway by DiMichele, Donna M

“…Hemophilia A is an X-linked hemorrhagic disorder characterized by a congenital absence or decrease in plasma clotting factor VIII, a procoagulation cofactor…”
Get full text

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study by Astermark, Jan, Donfield, Sharyne M., DiMichele, Donna M., Gringeri, Alessandro, Gilbert, Steven A., Waters, Jennifer, Berntorp, Erik

“…The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated…”
Get full text

The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort by Astermark, Jan, Donfield, Sharyne M., Gomperts, Edward D., Schwarz, John, Menius, Erika D., Pavlova, Anna, Oldenburg, Johannes, Kessing, Bailey, DiMichele, Donna M., Shapiro, Amy D., Winkler, Cheryl A., Berntorp, Erik

“…Studies of determinants of development of inhibitory Abs to factor VIII in people with hemophilia A indicate a complex process involving multiple factors. The…”
Get full text

Prior Publication Productivity, Grant Percentile Ranking, and Topic-Normalized Citation Impact of NHLBI Cardiovascular R01 Grants by Kaltman, Jonathan R, Evans, Frank J, Danthi, Narasimhan S, Wu, Colin O, DiMichele, Donna M, Lauer, Michael S

“…RATIONALE:We previously demonstrated absence of association between peer-review–derived percentile ranking and raw citation impact in a large cohort of…”
Get full text

Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics by DiMichele, Donna M.

“…The unprecedented emergence of novel therapeutics for both hemophilia A and B during the last half decade has been accompanied by the promise of even more…”
Get full text

Inhibitors in childhood hemophilia A: Genetic and treatment-related risk factors for development and eradication by DiMichele, Donna M.

“…The development of neutralizing antibodies remains a serious complication of hemophilia replacement therapy. Factor VIII inhibiting antibodies (inhibitors)…”
Get full text

Citation Impact of NHLBI R01 Grants Funded Through the American Recovery and Reinvestment Act as Compared to R01 Grants Funded Through a Standard Payline by Danthi, Narasimhan S, Wu, Colin O, DiMichele, Donna M, Hoots, W Keith, Lauer, Michael S

“…RATIONALE:The American Recovery and Reinvestment Act (ARRA) allowed National Heart, Lung, and Blood Institute to fund R01 grants that fared less well on peer…”
Get full text

Planning for the future workforce in hematology research by Hoots, W. Keith, Abkowitz, Janis L., Coller, Barry S., DiMichele, Donna M.

“…The medical research and training enterprise in the United States is complex in both its scope and implementation. Accordingly, adaptations to the associated…”
Get full text

Catalyzing innovation in clinical trial design and analysis at NHLBI: a funding opportunity for clinical trials in blood disorders by DiMichele, Donna M.

Get full text

Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors by Pipe, Steven W., Sabatino, Denise E., Nugent, Diane J., Hooper, W. Craig, Soucie, J. Michael, Keith Hoots, W., DiMichele, Donna M.

Get full text

Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors by Sabatino, Denise E., Pipe, Steven W., Nugent, Diane J., Soucie, J. Michael, Hooper, W. Craig, Hoots, W. Keith, DiMichele, Donna M.

“…Introduction The major complication of protein replacement therapy for haemophilia A is the development of anti‐FVIII antibodies or inhibitors that occur in…”
Get full text

End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings by Farrell, Ann T., Panepinto, Julie, Desai, Ankit A., Kassim, Adetola A., Lebensburger, Jeffrey, Walters, Mark C., Bauer, Daniel E., Blaylark, Rae M., DiMichele, Donna M., Gladwin, Mark T., Green, Nancy S., Hassell, Kathryn, Kato, Gregory J., Klings, Elizabeth S., Kohn, Donald B., Krishnamurti, Lakshmanan, Little, Jane, Makani, Julie, Malik, Punam, McGann, Patrick T., Minniti, Caterina, Morris, Claudia R., Odame, Isaac, Oneal, Patricia Ann, Setse, Rosanna, Sharma, Poornima, Shenoy, Shalini

“…To address the global burden of sickle cell disease and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug…”
Get full text

Management of factor VIII inhibitors by Dimichele, Donna M

“…The development of inhibitory alloantibodies to factor VIII (FVIII) is a major complication of clotting factor replacement therapy for hemophilia A. Inhibitor…”
Get full text

Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population by Shapiro, Amy D, Soucie, J Michael, Peyvandi, Flora, Aschman, Diane J, DiMichele, Donna M

“…Rare coagulation disorders (RCDs) present a considerable and multifaceted public health risk. Although inherited RCDs affect a minor segment of any local…”
Get full text

Inhibitor development in haemophilia B: an orphan disease in need of attention by DiMichele, Donna

“…Summary Factor IX (FIX) inhibitors develop in 1·5–3% of haemophilia B patients. Due to its low incidence compared with that in haemophilia A, few comparable…”
Get full text

Paroxysmal nocturnal hemoglobinuria in pediatric patients by Curran, Kevin J., Kernan, Nancy A., Prockop, Susan E., Scaradavou, Andromachi, Small, Trudy N., Kobos, Rachel, Castro-Malaspina, Hugo, Araten, David, DiMichele, Donna, O'Reilly, Richard J., Boulad, Farid

“…Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease in children. The most significant clinical features of PNH include: bone marrow failure,…”
Get full text

Immune tolerance therapy dose as an outcome predictor by DiMichele, Donna

“…The question of dose as a successful ITT outcome predictor in haemophilia A and B is an important one on many levels. Increased morbidity associated with…”
Get full text

Mutation in the factor VII hepatocyte nuclear factor 4α-binding site contributes to factor VII deficiency by Zheng, Xing-Wu, Kudaravalli, Rama, Russell, Theresa T, DiMichele, Donna M, Gibb, Constance, Russell, J Eric, Margaritis, Paris, Pollak, Eleanor S

“…Severe coagulant factor VII (FVII) deficiency in postpubertal dizygotic twin males results from two point mutations in the FVII gene, a promoter region T→C…”
Get full text